Cyprotex's Caco-2 permeability assay uses an established method that measures the rate of flux of a compound across polarised Caco-2 cell monolayers and from which the data generated can be used to predict in vivo absorption of drugs. The Caco-2 cell line is derived from a human colon carcinoma.
Preliminary BCS Permeability Classification Using Caco-2 Cell Monolayers This non-GLP assay is used to determine a preliminary BCS permeability classification by measuring the permeability of a test compound through Caco-2 cell monolayers in both the apical-to-basolateral and basolateral-to-apical direction Catalog number EA903.
In the absence of an optimized and validated protocol for the Caco-2 cell drug permeability assay, a more general approach is considered to standardize a method within a laboratory. An assay was.
GLP BCS Permeability Classification Using Caco-2 Cell Monolayers This GLP assay is used to determine the BCS permeability classification of a test compound across Caco-2 cell monolayers at three concentrations and two pH values. Catalog number EA904. Required from Customer.
The aim of this study was to find out the optimal experimental conditions for Caco-2 cell cul-ture (time and density) and permeability assays (diffusion system and drug concentration) in order to study the in vitro drugs permeability as a predictive method for drug absorption across intestinal epitheli-um.
The Caco-2 cell membrane permeability of three series of peptides and endothelin antagonists could be predicted by a theoretical model that considered both the polar (PSA d) and nonpolar (NPSA d) parts of the dynamic molecular surface area of the molecules. 97,131 The three peptide series were AcHN-X-phenethylamides, AcHN-XD-Phe-NHMe derivatives and d -Phe-oligomers.
The parallel artificial membrane permeability assay is one of Cyprotex's in vitro ADME screening services. Cyprotex deliver consistent, high quality data with cost-efficiency that comes from a highly automated approach. The Parallel Artificial Membrane Permeability Assay (PAMPA) is used as an in vitro model of passive, transcellular permeation.
The purpose of this study was to investigate labetalol as a potential high permeability reference standard for the application of Biopharmaceutics Classification Systems (BCS). Permeabilities of labetalol and metoprolol were investigated in animal intestinal perfusion models and Caco-2 cell monolayers.
The Caco-2 bidirectional permeability assay is a useful tool in preclinical drug discovery to predict the likelihood of a compound being able to cross the barrier posed by the gastrointestinal.
The aim of this research has been to determine the biperiden hydrochloride permeability in Caco-2 model, in order to classify it based on the Biopharmaceutics Classification System (BCS). The World Health Organization (WHO) as well as many other authors have provisionally assigned the drug as BCS class I (high solubility-high permeability) or III (high solubility-low permeability), based on.
While the Caco-2 assay is the gold standard for in vitro permeability assessment, interpretation of the results from such assays needs careful attention due to high lab-to-lab variability.
The Biopharmaceutics Classification System (BCS) is the scientific basis for classifying drugs based on their aqueous solubility and intestinal permeability that supports in vivo bioavailability and bioequivalence waivers for immediate-release solid dosage form drugs. One requirement of the BCS is that the permeability method must be validated.
If high permeability is inferred by means of an in vitro cell system, permeability independent of active transport should be proven as outlined in Annex I, “Caco-2 cell permeability assay method considerations”. If high permeability is not demonstrated, the drug substance is considered to have low permeability for BCS classification purposes.
The predictive power of the model was similar to that of the caco-2 cells for passively absorbed compounds that showed good permeability 19. For those that were poorly permeable or were actively transported, the model was unable to accurately present the degree of absorption; for the latter this is due to the minimal transporters expressed by the MDCK cells 19, resulting in a poor IVIVC.
Eurofins Discovery offers a comprehensive panel of in vitro permeability services to provide accurate predictions of in vivo oral absorption for your compounds. For rapid assessment of membrane permeability, we provide both standard and custom bidirectional permeability assays in multiple cell lines including human Caco-2 and MDCK cells.
Permeability of Chondroitin Sulfate Across Caco-2 Cell Monolayers: The growth, maturation, and seeding of Caco-2 cells have been previously described.40 Caco-2 cells with a passage number between 45 and 55 were used in an effort to derive Caco-2 monolayers with consistent morphological and biochemical properties. Caco-2 cells.
Caco-2 Permeability Measurement December 18, 2009 - pION Biopharma Services and SBH Sciences have entered an agreement to co-develop and market Caco-2 permeability measurement. The new high quality testing service is builds upon the expertise of p ION in drug adsorption measurements and SBH Sciences, in cell-based assays.
The Caco-2 permeability assay measures the permeability of compounds through a human intestinal epithelial cell barrier. Therefore, the endpoint measured is intestinal permeability (expressed as apparent permeability - Papp value). The test method appears more relevant for drug permeability studies.
Caco-2 monolayer model is widely used (10,11) to estimate and predict the intestinal permeability of various flavonoids (5,12), because it is derived from human colonic adenocarcinoma and shares many morphological (e.g., microvilli) and functional properties with mature enterocytes.